Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results
January 11 2022 - 7:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company commercializing the CellFX® System powered by
Nano-Pulse Stimulation™ (NPS™) technology, today announced
preliminary unaudited fourth quarter 2021 financial and operational
results.
Recent Highlights:
- Preliminary unaudited full year 2021 revenue is expected to be
in the range of $1.3 million to $1.4 million, including preliminary
unaudited fourth quarter 2021 revenue of approximately $750
thousand
- Completed the first two commercial sales of CellFX Systems in
the fourth quarter of 2021
- Transitioned 17 Controlled Launch Program participants to
commercial use of their acquired CellFX System, bringing the total
number of commercial conversions to 29 at the end of the fourth
quarter of 2021
- Completed onboarding CellFX Controlled Launch Program
participants, increasing the total number of program participants
to 70. Six clinics have opted out of the program to date.
“We are proud of our accomplishments in 2021,” said Darrin
Uecker, President and CEO of Pulse Biosciences. “We achieved
regulatory approval for the CellFX System in the U.S., Europe and
Canada, onboarded Controlled Launch Program participants, expanded
commercialization across each geography and continued to advance
our clinical and regulatory initiatives. These achievements
position Pulse Biosciences to drive meaningful growth in 2022 and
beyond as we leverage the full potential of NPS technology in
dermatology and other medical specialties.”
The Company’s fourth quarter 2021 financial results are
preliminary and are subject to the completion of the Company’s 2021
audit. Complete fourth quarter and full year 2021 financial results
will be announced in March.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nano-Pulse Stimulation technology delivers nano-second pulses of
electrical energy to non-thermally clear cells while sparing
adjacent non-cellular tissue. The CellFX® System is the first
commercial product to harness the distinctive advantages of NPS
technology to treat a variety of applications for which an optimal
solution remains unfulfilled. The initial commercial use of the
CellFX System is to address a range of dermatologic conditions that
share high demand among patients and practitioners for improved
dermatologic outcomes. Designed as a multi-application platform,
the CellFX System offers customer value with a utilization-based
revenue model. Visit pulsebiosciences.com to learn more.
To stay informed about the CellFX System, please visit
CellFX.com and sign-up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the
stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to Pulse Biosciences’ expectations regarding
the commercialization of the CellFX System to drive Company growth,
such as statements relating to the effectiveness of the Company’s
NPS technology and the CellFX System to improve patient outcomes,
statements concerning the value of the Company’s utilization-based
revenue model, statements relating to the Company’s pipeline of
product candidates, market opportunities and commercial launch
plans, including statements about the Company’s ability to pursue
applications for NPS technology outside of dermatology, and other
future events. These statements are not historical facts but rather
are based on Pulse Biosciences’ current expectations, estimates,
and projections regarding Pulse Biosciences’ business, operations
and other similar or related factors. Words such as “may,” “will,”
“could,” “would,” “should,” “anticipate,” “predict,” “potential,”
“continue,” “expects,” “intends,” “plans,” “projects,” “believes,”
“estimates,” and other similar or related expressions are used to
identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Pulse Biosciences’ control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Pulse
Biosciences’ filings with the Securities and Exchange Commission.
Pulse Biosciences undertakes no obligation to revise or update
information in this release to reflect events or circumstances in
the future, even if new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220111005576/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Media: Tosk Communications Nadine D. Tosk 504.453.8344
nadinepr@gmail.com or press@pulsebiosciences.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Sep 2023 to Sep 2024